For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Imusera/Gilenya Don’t Delay Disability Progression in Primary Progressive MS, MHLW Orders Label Revisions
July 6, 2016
- MHLW OKs Sanofi’s PCSK9 Inhibitor, Other Drugs
July 5, 2016
- MHLW to Issue “Blue Book” on Quality of Generics by March-End
July 1, 2016
- It’s Now Up to UK Govt to Decide on Future Action after Brexit Vote: EMA Spokesperson
June 30, 2016
- MHLW Begins Interim Review of 10-Year Strategy on Hepatitis Research
June 29, 2016
- MHLW Restresses Risk of HBV Reactivation for 8 Hep C Drugs
June 29, 2016
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
- Registration System for Prevention of Dementia to Begin Operation; Will Provide Info on Clinical Research, Trials
June 24, 2016
- MHLW Official Vows to Swiftly Present Proposal on “Optimal Use of Innovative Drugs”: Chuikyo
June 23, 2016
- Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya
June 23, 2016
- Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well
June 22, 2016
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
- MHLW Unveils List of Switch OTCs Eligible for Tax Break
June 20, 2016
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…